CPC A61K 31/352 (2013.01) [A61K 31/01 (2013.01); A61K 31/015 (2013.01); A61K 31/045 (2013.01); A61K 31/05 (2013.01); A61K 31/4425 (2013.01); A61K 31/46 (2013.01); A61K 31/5513 (2013.01); A61K 31/5517 (2013.01); A61K 31/658 (2023.05); A61K 45/06 (2013.01); C07D 451/10 (2013.01); C07D 471/08 (2013.01)] | 16 Claims |
1. A method for treating symptoms caused by exposure to sarin or aldicarb, comprising: administering a composition comprising about 0.0001 mg to about 10 mg of tetrahydrocannabinol (THC) and about 3 mg to about 400 mg cannabidiol (CBD) to a subject exposed to sarin or aldicarb, wherein the administration of the THC/CBD composition is oral, nasal, buccal, vapor, sublingual, or parenteral.
|